Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Haluska

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical SpecimensCourtney L Andersen, Matthew J Sikora, Michelle M Boisen, et al.
Mayo Clinic Proceedings|July 11, 2008
Malignant melanoma in the 21st century: the emerging molecular landscapeAleksandar Sekulic, Paul Haluska, Arlo J Miller, et al.
Oncotarget|April 20, 2017
Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypesMadalene A Earp, Rama Raghavan, Qian Li, et al.
Scientific Reports|April 14, 2021
Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) settingAnn L Oberg, Ethan P Heinzen, Xiaonan Hou, et al.
Cancer Research|November 16, 2014
Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancerEvanthia Galanis, Pamela J Atherton, Matthew J Maurer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group StudyRoisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
Journal of the National Cancer Institute|May 23, 2018
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic VirotherapyCheyne Kurokawa, Ianko D Iankov, S Keith Anderson, et al.
Gynecologic Oncology|September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinomaMariam M AlHilli, Marc A Becker, S John Weroha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2014
Tumorgrafts as in vivo surrogates for women with ovarian cancerS John Weroha, Marc A Becker, Sergio Enderica-Gonzalez, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical SpecimensCourtney L Andersen, Matthew J Sikora, Michelle M Boisen, et al.
Mayo Clinic Proceedings|July 11, 2008
Malignant melanoma in the 21st century: the emerging molecular landscapeAleksandar Sekulic, Paul Haluska, Arlo J Miller, et al.
Oncotarget|April 20, 2017
Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypesMadalene A Earp, Rama Raghavan, Qian Li, et al.
Scientific Reports|April 14, 2021
Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) settingAnn L Oberg, Ethan P Heinzen, Xiaonan Hou, et al.
Cancer Research|November 16, 2014
Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancerEvanthia Galanis, Pamela J Atherton, Matthew J Maurer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group StudyRoisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
Journal of the National Cancer Institute|May 23, 2018
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic VirotherapyCheyne Kurokawa, Ianko D Iankov, S Keith Anderson, et al.
Gynecologic Oncology|September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinomaMariam M AlHilli, Marc A Becker, S John Weroha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2014
Tumorgrafts as in vivo surrogates for women with ovarian cancerS John Weroha, Marc A Becker, Sergio Enderica-Gonzalez, et al.
Pageof 7